UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000046551
Receipt No. R000053112
Scientific Title The efficiency of hepatopancreatoduodenectomy for biliary malignancy
Date of disclosure of the study information 2022/01/05
Last modified on 2022/01/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The efficiency of hepatopancreatoduodenectomy for biliary malignancy
Acronym The efficiency of hepatopancreatoduodenectomy for biliary malignancy
Scientific Title The efficiency of hepatopancreatoduodenectomy for biliary malignancy
Scientific Title:Acronym The efficiency of hepatopancreatoduodenectomy for biliary malignancy
Region
Japan

Condition
Condition Biliary malignancy
Classification by specialty
Hepato-biliary-pancreatic surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To determine the appropriate indication for HPD in patients with advanced biliary tract cancer by examining the relationship between 5-year survival and clinical information.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 5-year survival rate
Key secondary outcomes (1) Perioperative outcomes (complications and mortality)
2) Association between clinical factors and long-term prognosis

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1) Those who have undergone HPD
2) Those who do not refuse to participate in this study.
Key exclusion criteria (1) Patients with insufficient clinical data
(2) Other patients who are judged by the principal investigator to be unsuitable as research subjects.
Target sample size 61

Research contact person
Name of lead principal investigator
1st name Takehiro
Middle name
Last name Noji
Organization Hokkaido University Hosp
Division name Gastroenterological surgery II
Zip code 060-8638
Address Kita14 Nishi5, Kita-ku, Sapporo city, Japan
TEL 0117067714
Email drnoji@med.hokudai.ac.jp

Public contact
Name of contact person
1st name Takehiro
Middle name
Last name Noji
Organization Hokkaido University Hospital
Division name Gastroenterological surgery II
Zip code 060-8638
Address Kita14 Nishi5, Kita-ku, Sapporo city
TEL 0117067714
Homepage URL
Email drnoji@med.hokudai.ac.jp

Sponsor
Institute Hokkaido University Hosp
Institute
Department

Funding Source
Organization Self funding
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization IRB Hokkaido University Hospital
Address Kita14 Nishi5, Kita-ku, Sapporo city, Hokkaido Japan
Tel 011-716-1161
Email crjimu@huhp.hokudai.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2022 Year 01 Month 05 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2022 Year 01 Month 05 Day
Date of IRB
2022 Year 01 Month 31 Day
Anticipated trial start date
2022 Year 01 Month 05 Day
Last follow-up date
2026 Year 08 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information We will collect medical information on the research subjects up to 31 August 2026 and investigate the following items

1) Background information: age, sex, medical history, diagnosis, treatment history, performance status
2) Hematological examination results: hemoglobin, white blood cell count, white blood cell fraction and platelet count
3) Blood chemistry test results: total protein, albumin, Na, K, serum tumor marker (CEA/CA19-9)
4) CT, MRI, ultrasound and cholangiogram results
5) Results of histopathological examination (histological type, degree of progression, lymph node metastasis)
(6) Operative procedure, operative time, amount of blood loss
7) Postoperative course (presence of complications)
(viii) Type and duration of postoperative treatment.
(viii) Type and duration of postoperative treatment (ix) Time to recurrence, site of recurrence, prognosis of life, date of last hospital visit, cause of death

Management information
Registered date
2022 Year 01 Month 05 Day
Last modified on
2022 Year 01 Month 05 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053112

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.